知镜 Cognispect · 医学文献与研究工作台

Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.

Amamoo J, Wang Y, Liu H, Sundar M, Song Y, Xie L, Mehanna S, Noone J, Swift C, Weir MR.
Advances in therapy · 2026-09-23 · PMID 42776473

文献摘要

Introduction Once-weekly (OW) semaglutide has shown renal benefits in clinical trials for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This study compared clinical outcomes between OW semaglutide and selected oral glucose-lowering medications in real-world settings. Methods Adults with T2D and CKD were identified from the Optum's de-identified Clinformatics ® Data Mart Database (01/01/2016-06/30/2023). Two samples were included: patients ineligible for or with suboptimal response to sodium-glucose cotransporter type 2 inhibitor (SGLT2i) (sample 1) and patients meeting the eligibility criteria for renal outcome analysis [sample 2; no estimated glomerular filtration rate (eGFR) 2 during the 6 months before the index date and no evidence of dialysis, kidney transplantation, or kidney failure at baseline]. In sample 1, glycated hemoglobin (HbA1c), eGFR, body weight, and systolic blood pressure (SBP) were described and compared using linear mixed-effects models. In sample 2, composite renal outcome consisting of dialysis, kidney transplantation, sustained eGFR 2 , or all-cause death, was evaluated and compared using Cox proportional hazard model. Results Using model-based estimates at 12 months, OW semaglutide was associated with greater reductions in HbA1c (- 0.54%), body weight (- 6.69 kg), SBP (- 3.63 mmHg), and greater improvement in eGFR (2.06 mL/min/1.73 m 2 ) compared to controls (all P Conclusions In real-world practice, OW semaglutide has been associated with sustained benefits in glycemic control, eGFR improvement, weight loss, and SBP reduction over selected oral glucose-lowering medications among patients with T2D and CKD who were ineligible for or with suboptimal response to SGLT2i. It has also been associated with a reduced risk of the composite renal outcome in patients meeting the eligibility criteria for the renal outcome analysis.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。